Sol-Can® A Citrate
Vælg en kategori eller underkategori
Sol-Can® A Citrate is a citric acid hemodialysis concentrate in the mixing ratio 1+44
In general, citric acid is a natural metabolite that is processed through the citrate cycle. Citric acid is biocompatible and physiologically compatible for reliable tolerance, as citric acid is a weak organic acid that can be rapidly metabolized by the body.1 Sol-Can® A Citrate is an alternative concentrate designed to enhance comfort for patients and the entire renal care center by potentially reducing side effects and promoting patient well-being.
Fordele
Studies show that citrate has the potential to improve the quality of different aspects of dialysis treatments as:
- Reduction of side effects, e.g., reduction of postdialysis alkalemia2
- Supports patient well-being, e.g., antiinflammatory effect,3 less calcifying profile,2 hemodynamic tolerance2
- Citrate can be seen as one component for further optimizing heparin management4,5
Unlike acetate, which can have a noticeable smell, Sol-Can® A Citrate is nearly odorless6 and can thus enhance comfort at the renal care center. This can be particularly beneficial for patients sensitive to strong odors and creates a more pleasant working environment for nurses and nephrologists.
“Citrate concentrate has been an essential part of our clinical practice for over 10 years and is now our standard. We use it as one component of managing inflammation.” Dr. Simonetta Vastano, POS Rome
1 Safránek R, Moučka P, Vávrová J, Palička V, Pavlíková L, Sulková SD. Changes of serum calcium, magnesium and parathyroid hormone induced by hemodialysis with citrate-enriched dialysis solution. Kidney Blood Press Res. 2015;40(1):13–21.
2 de Sequera Ortiz P, Pérez García R, Molina Nuñez M, Muñoz González RI, Álvarez Fernández G, Mérida Herrero E, Camba Caride MJ, Blázquez Collado LA, Alcaide Lara MP, Echarri Carrillo R; en representación del grupo del estudio ABC-treat; Grupo del estudio ABC-treat. Prospective randomised multicentre study to demonstrate the benefits of haemodialysis without acetate (with citrate): ABC-treat Study. Acute effect of citrate. Nefrologia (Engl Ed). 2019 Jul - Aug;39(4):424 - 433. English, Spanish. doi: 10.1016/j.nefro.2018.11.002. Epub 2019 Jan 24. PMID: 30686542.
3 Grundström G, Christensson A, Alquist M, Nilsson LG, Segelmark M. Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short-term safety and fluid
biocompatibility. BMC Nephrol. 2013 Oct 9;14:216. doi: 10.1186/1471-2369-14-216. PMID: 24103587; PMCID: PMC4124727
4 Molina Nuñez M, de Alarcón R, Roca S, Álvarez G, Ros MS, Jimeno C, Bucalo L, Villegas I, García MÁ. Citrate versus acetate-based dialysate in on-line haemodiafiltration: a prospective cross-over study. Blood Purif. 2015;39(1 - 3):181 - 187. doi: 10.1159/000371569. PMID: 25791278.
5 Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A, Carter M, Sergeyeva O, Korth L, Maunsell E, Zhu Y, Krishnan M, Diaz-Buxo JA. Effects of citrate acid concentrate (Citrasate®) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif. 2012;33(1 - 3):199 - 204. doi: 10.1159/000334157. Epub 2012 Jan 20. PMID: 22269855.
6 Data on file: Medical Safety Data Sheet, Number 0056-0412 MSDS.